Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Shanghai Pulmonary Hospital, Tongji University, Guangdong Academy of Medical Sciences, Guangdong General Hospital, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Jiangsu Cancer Hospital, Academy of Military Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Capital Medical University, Beijing Chest Hospital, Peking University, Peking University Cancer Hospital, Shanghai Jiao Tong University, Shanghai Chest Hospital, Sun Yat-sen University Cancer Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Sun Yat-sen University, Central South University, Xiangya Hospital Central South University, Second Xiangya Hospital of Central South University, Hunan Cancer Hospital, Cancer Hospital of Shantou University Medical College, Shantou University, Renji Hospital, First Affiliated Hospital of Soochow University, Soochow University, Zhejiang Cancer Hospital, Second Military Medical University, Harbin Institute of Petroleum, Nanfang Hospital, Southern Medical University